TY - JOUR
T1 - New Treatment Options for Patients with Metastatic Prostate Cancer
T2 - What Is the Optimal Sequence?
AU - Van Dodewaard-De Jong, Joyce M.
AU - Verheul, Henk M.W.
AU - Bloemendal, Haiko J.
AU - De Klerk, John M.H.
AU - Carducci, Michael A.
AU - Van Den Eertwegh, Alfons J.M.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.
AB - Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.
KW - Chemotherapy
KW - Hormonal therapy
KW - Immunotherapy
KW - Prostate cancer
KW - Radiopharmaceuticals
UR - http://www.scopus.com/inward/record.url?scp=84930828589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930828589&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2015.01.008
DO - 10.1016/j.clgc.2015.01.008
M3 - Review article
C2 - 25704270
AN - SCOPUS:84930828589
SN - 1558-7673
VL - 13
SP - 271
EP - 279
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 4
ER -